News | Ventricular Assist Devices (VAD) | June 30, 2022

FDA Provides Update on Medtronic's HeartWare Ventricular Assist Device (HVAD) System

Medtronic conducted a recall to inform health care providers and patients of battery performance issues.

June 30, 2022 — Today, the U.S. Food and Drug Administration (FDA) is providing updates to the FDA website to include information on recent recalls conducted by Medtronic. These recalls include information on battery performance issues as well as the availability of a modified software for select patients.

On June 3, 2021, Medtronic stopped the sale and distribution of the HeartWare Ventricular Assist Device (HVAD) system given the increased risk of mortality and neurological adverse events in patients using the device, and a malfunction where the device may fail to restart. Both problems may lead to serious injuries or death.

The FDA continues to work with Medtronic to ensure the health and safety of device users, which remains our highest priority. This includes ensuring current patients continue to receive appropriate follow up monitoring and Medtronic continues to meet its obligations to support patients and health care providers.

Updates

June 30, 2022 – Medtronic conducted a recall to inform health care providers and patients of battery performance issues. All health care providers and patients are now being made aware of the battery welding defect that was previously communicated to affected providers in the May 2022 recall. Medtronic also provided information about battery electrical faults caused by an interaction between the battery software and an internal component.

June 7, 2022 – Medtronic initiated a recall to inform health care providers who are following certain patients (those with a pump in the subset identified at higher risk of experiencing a failure to restart) about a controller with modified software that is available as a back-up if the pump has stopped and the standard controller is unable to restart the pump.

Additionally, the recent actions taken by Medtronic to correct translation and labeling errors have been added to the Medtronic HeartWare Recalls below.

The FDA remains committed to providing updates about the safety profile of the HeartWare Ventricular Assist Device (HVAD) System. For more information: www.fda.gov

 

Related HVAD Content:

Medtronic Recalls HeartWare HVAD System Batteries Due to Battery Failure

Medtronic Recalls HVAD Pump Implant Kit for Pump Weld Defect

Medtronic Recalls HVAD Pump Implant Kits After 2 Deaths and 19 Serious Injuries

Class I Recall Issued for Medtronic HeartWare HVAD Pump

Medtronic HeartWare HVAD System Approved for Destination Therapy

FDA, Medtronic Expand HeartWare VAD Recall, Announces New Recall of VAD Component

FDA Announces Two HeartWare HVAD System Class 1 Recalls

New Heart Assist Pump Allows Minimally Invasive Approach at Vanderbilt Heart and Vascular Institute

Related Content

News | Heart Failure

August 8, 2022 — A major risk factor for diabetes, insulin resistance occurs when the cells of the body do not respond ...

Home August 08, 2022
Home
News | Heart Failure

August 5, 2022 — For people with coronary heart disease, beta-blockers can improve survival and quality of life, while ...

Home August 05, 2022
Home
News | Heart Failure

July 27, 2022 — The world’s first HIV-positive to HIV-positive heart transplant has been successfully performed at ...

Home July 27, 2022
Home
News | Heart Failure

July 27, 2022 — Researchers from RCSI University of Medicine and Health Sciences have developed a new lab-based model of ...

Home July 27, 2022
Home
News | Heart Failure

July 20, 2022 — Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease and ...

Home July 20, 2022
Home
News | Heart Failure

July 15, 2022 — The American Heart Association, the leading voluntary organization devoted to longer, healthier lives ...

Home July 15, 2022
Home
News | Heart Failure

July 13, 2022 — Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today ...

Home July 13, 2022
Home
News | Heart Failure

July 12, 2022 — Pesticides and heavy metals in soil may have detrimental effects on the cardiovascular system, according ...

Home July 12, 2022
Home
News | Heart Failure

July 7, 2022 — Tenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver ...

Home July 07, 2022
Home
News | Heart Failure

June 29, 2022 — A spiral wave of electrical activity in the heart can cause catastrophic consequences. One spiral wave ...

Home June 29, 2022
Home
Subscribe Now